Mild or moderate hemophilia A without FVIII inhibitors research hub

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors

This study looks at a new medicine called Hemlibra for people with mild or moderate haemophilia A. It checks how safe and effective it is, how the body handles it, and if it helps reduce bleeding episodes in adults.